Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 31;9(2):e0024621.
doi: 10.1128/Spectrum.00246-21. Epub 2021 Sep 15.

Genetic Determinants of Intrinsic Antibiotic Tolerance in Mycobacterium avium

Affiliations

Genetic Determinants of Intrinsic Antibiotic Tolerance in Mycobacterium avium

William M Matern et al. Microbiol Spectr. .

Abstract

The Mycobacterium avium complex (MAC) is one of the most prevalent causes of nontuberculous mycobacteria pulmonary infection in the United States, and yet it remains understudied. Current MAC treatment requires more than a year of intermittent to daily combination antibiotic therapy, depending on disease severity. In order to shorten and simplify curative regimens, it is important to identify the innate bacterial factors contributing to reduced antibiotic susceptibility, namely, antibiotic tolerance genes. In this study, we performed a genome-wide transposon screen to elucidate M. avium genes that play a role in the bacterium's tolerance to first- and second-line antibiotics. We identified a total of 193 unique M. avium mutants with significantly altered susceptibility to at least one of the four clinically used antibiotics we tested, including two mutants (in DFS55_00905 and DFS55_12730) with panhypersusceptibility. The products of the antibiotic tolerance genes we have identified may represent novel targets for future drug development studies aimed at shortening the duration of therapy for MAC infections. IMPORTANCE The prolonged treatment required to eradicate Mycobacterium avium complex (MAC) infection is likely due to the presence of subpopulations of antibiotic-tolerant bacteria with reduced susceptibility to currently available drugs. However, little is known about the genes and pathways responsible for antibiotic tolerance in MAC. In this study, we performed a forward genetic screen to identify M. avium antibiotic tolerance genes, whose products may represent attractive targets for the development of novel adjunctive drugs capable of shortening the curative treatment for MAC infections.

Keywords: DNA sequencing; bioinformatics; mechanisms of action; molecular genetics; persistence; tolerance.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Bar chart showing the effect size of each statistically significant mutant. Each bar represents a single gene. A negative value represents a hypersusceptible mutant, while a positive value signifies that a mutant is less susceptible (hypertolerant) to the antibiotic. (A) Clarithromycin, (B) ethambutol, (C) moxifloxacin, (D) rifabutin.
FIG 2
FIG 2
Venn diagram of identified hypersusceptible (A) and hypertolerant transposon mutants (B). Note that in A, the set of ethambutol-hypersusceptible mutants has been partitioned into two sets (both in yellow). Partitioning in this way greatly simplifies the diagram. Gene names in each category can be found in Table S1 and S2.
FIG 3
FIG 3
Schematic of transposon mutant screen to identify hypersusceptible mutants following exposure to multiple doses of various antibiotics in liquid culture. After antibiotic exposure, cultures were regrown on solid agar to enrich for surviving bacteria. After regrowth, DNA was extracted and prepared for Tn-seq analysis. Hypersusceptible mutants were identified using a nonparametric statistical approach.

References

    1. Falkinham JO. 1996. Epidemiology of infection by nontuberculous mycobacteria. Clin Microbiol Rev 9:177–215. doi:10.1128/CMR.9.2.177. - DOI - PMC - PubMed
    1. Wolinsky E. 1979. Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis 119:107–159. doi:10.1164/arrd.1979.119.1.107. - DOI - PubMed
    1. Inderlied CB, Kemper CA, Bermudez LE. 1993. The Mycobacterium avium complex. Clin Microbiol Rev 6:266–310. doi:10.1128/CMR.6.3.266. - DOI - PMC - PubMed
    1. Ito Y, Hirai T, Maekawa K, Fujita K, Imai S, Tatsumi S, Handa T, Matsumoto H, Muro S, Niimi A, Mishima M. 2012. Predictors of 5-year mortality in pulmonary Mycobacterium avium-intracellulare complex disease. Int J Tuber Lung Dis 16:408–414. doi:10.5588/ijtld.11.0148. - DOI - PubMed
    1. Prevots DR, Shaw PA, Strickland D, Jackson LA, Raebel MA, Blosky MA, Montes de Oca R, Shea YR, Seitz AE, Holland SM, Olivier KN. 2010. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med 182:970–976. doi:10.1164/rccm.201002-0310OC. - DOI - PMC - PubMed

Publication types

MeSH terms